Anon-International Data Collection Study Todetermine Therole of Usage of Multivitamins Capsules in Diabetic Patient as an Add-On Therapy

S.S.V.S. Swetha*, Ch. Bindu Sri*, Aseem Nazia. Shaik, A. Lakshmi Gnapika

*Associate Profeesor, Hod Of Pharmacology, Nri College Of Pharmacy, Pothavarappadu Iv Year B. Pharmacy Students, Nri College Of Pharmacy, Pothavarappadu

Date of Submission: 05-08-2024 Date of Acceptance: 15-08-2024

ABSTRACT: Diabetes management often involves multiple strategies to maintain blood glucose levels and prevent complications. While the primary treatments include lifestyle modification and pharmacotherapy, the addition of multivitamins further offer benefits. This interventionaldata collection study aims to assess the role of multivitamins capsules as an add- on the therapy in diabetic patients i.e., the impact of multivitamins capsules as an adjunct therapy in diabetic patients. The research categorized 20 patients into two groups. Group A included 10 patients with a diabetic history who took multivitamins tablets as an adjunct therapy, while group B, also comprising 10 patients, did not use multivitamins. Researches gathered and analysed the past medical and medication histories of both groups. In Group A, multivitamins consumption among the diabetic population reached 100%. Conversely, Group B had a 0% consumption rate of multivitamins. The mean quality of life score in Group A was 15.2%, indicative of the benefits of multivitamins uses. In Group B, the mean quality of life score was 3.6%, reflecting the absence of multivitamins use. The study concluded that diabetic patients who included multivitamins as an adjunct therapy enjoyed a notably better quality of life compared to those who did not. This finding highlighted the potential advantages multivitamins supplementation in enhancing the quality of life for individuals with diabetes.

KEYWORDS: -Multivitamins,Supplementation, Blood glucose levels, Adjunct, Diabetes mellitus,Quality life

I. INTRODUCTION MULTIVITAMIN: -

A multivitamin is a preparation intended to serve as a dietary supplement with vitamins, dietary minerals, and other nutritional elements. Such preparations are available in the form of tablets, capsules, pastilles, powders, liquids or injectable formulations.

Multivitamins are most commonly used by the people with poor nutrition or those at high risk of macular degeneration.

DIABETES MELLITUS:

Decreased or absent insulin activity results in diabetes mellitus, a condition of high sugar level [hyperglycaemia]. There are mainly two types of this disease i.e.; Diabetes Mellitus Type -1 & Diabetes Mellitus type -2.

In Diabetes Mellitus type-1:

The beta cells are destroyed by an autoimmune reaction so that insulin can no longer be synthesized or be secreted into the blood.


In Diabetes Mellitus Type-2:

The destruction of beta cells is less pronounced than in type-1, & is not due to an autoimmune process. Instead, there is accumulation of amyloid in the pancreatic islets, which likely disrupts their anatomy & physiology.

Insulin was the first peptide hormone which was discovered. Frederick Banting & Charles Herbert-Best, working in the laboratory of J.J.R. Macleod at the University of Toronto, where the first to isolate insulin from dog pancreas in 1921.

Frederick Sanger sequenced the amino acid structure in 1951, which made insulin the first protein to be fully sequenced. The crystal structure of insulin in the solid state was determined by Dorothy-Hodgkin in 1969.

Insulin is also the first protein to be chemically synthesized & produced by DNA recombinant technology. It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system. [1]



Type 1 diabetes

BACKGROUND OF THE STUDY:

Multivitamins are the most common supportive therapy for diabetes mellitus patients & the current study is designed to determine the role & usage of multivitamin as an add on therapy.

Rationale of study:

This study is mainly used to determine the percentage of patients who are having good activity & good quality of life compared in diabetic patients who are not consuming any add on therapy. [3]

Study objective:

The study objective is to prove role & usage of multivitamins as an add on drug in diabetic patients.

STUDY DESIGN:

This study is designed to collect the patients in a single visit & the following data will be captured.

The acceptance of the patient to give their data in the form of informed consent form.

Patient past medical history will be collected.

The patient's data will be collected in 2 groups.

Group-1:

Data:

The patient's data will be categorised in two groups.

In group-1 the patient should use enough multivitamin as an add on therapy &should be diabetic patient.

Group-2:

Data:

In group-2 the patient should not use multivitamin as an add on drug & they should be diabetic patients.^[4]

INSTITUTIONAL ETHICS COMMITTEE REVIEW

Before the start of the study protocol, ICF, and any other essential documents will be submitted to the institutional ethics committee with a cover letter or form listing the documents submitted their dates and versions of issue for which approval is sought.

As per institutional requirements, the study protocol & any other appropriate documents will be submitted to scientific committee for approval. The study team will also keep the documentation of study approval by internal scientific committee as per institutional requirements.

CONFIDENTIALITY

If patient's name appearson any other document collected, the name must be obliterated before the document is transmitted into CRF subjects will be informed that all personal information made available for the inspection will be handled in the strictest confidence & in accordance with all state, local &federal data protection.

CASE REPORT FORMS

The study case report form[CRF] is the primary source of the data collection of the study. All the data requested on the CRF must be recorded. All missing data must be explained. If a space on the CRF is left blank because the procedure was not done or the question was not

asked, write "N/D". if the item is not applicable to the individual case, write "N/A". All entries should be printed legibly in black ink. All such changes should be initiated & dated. [5]

DO NOT ERASE OR WHITE OUT ERRORS.

For clarification of illegibly or uncertain entries, print the clarification above the item, then initial & date it.

INFORMED CONSENT FORM:

The basic requirement of the study to prove the acceptance of the patient or the participant to give their volunteer acceptance to participate in the

Sample size & the statistical analysis plan:

The total sample size calculated for the study in two groups was twenty

Group 1: n = 10

Group 2: n = 10

Total n No. of patient's data planned to collect in the study was 20.

Publication Policies:

All information collected in the study will be published on the name of students& on behalf of

TABLE:-1

ANNEXURES:

Annexure – 1	Informed consent form
Annexure – 2	Case report form
Annexure – 3	Patient quality of life questionnaires

TABLE:-2

PROTOCOL SYNOPSIS:-

PROTOCOL TITLE	"A NON-INTERNATIONAL DATA COLLECTION STUDY TO DETERMINETHE ROLE OF MULTIVITAMIN COMSUMPTION BY DIABETIC PATIENTS AS AN ADD-ON THERAPY"		
protocol id	NRI/03/2022		
Version and date	Version no 1.0, dated: 01/03/2022		
Data collection centres	01		
Study period	1 month		
Total no of population selected for data collection	20 patients non - international data collection		
No of study visits	01		
No of groups	02		
Study type	Non-international data collection		
Study objective	The objective of the study is to determine the role o multivitamins consumption by diabetic patients as an add-on therapy		
Primary end points	No of patients having their improvement of quality of life.		
Secondary end points	Difference of activity in diabetic patients comparing patient who consuming not consuming multivitamins as an add- on therapy		
Study population	Male and female of age 18 yrs, and above who are diagnosed with diabetic mellitus type 1 and diabetic mellitus type 2.		
Inclusion criteria	Patients of age 18 years and above who are diagnosed with diabetic mellitus type 1 and diabetic mellitus type 2.		
Exclusion criteria	Non diabetic patients Diabetic patient who are on insulin therapy patients of low BMI		



Volume 6, Issue 4, July. – Aug. 2024 pp 263-272 www.ijdmsrjournal.com ISSN: 2582-6018

	Patients who suffering from severe chronic diseases
Data capturing	paper CRF
	patient quality of life questionnaires

FIGURE:-2





Volume 6, Issue 4, July. – Aug. 2024 pp 263-272 www.ijdmsrjournal.com ISSN: 2582-6018

FIGURE:-3 Case Report Form, Virgin No. LA, David HUNGSTON 0 1 Police hills! CASE REPORT FORM Study Title: "A non-interventional data collection study to determine the role of auditoliums communition by diabatic patients as an old-on therapy". Study Code: NUUS 2022 Version Not LO, Dated 91/07/2022 Patient Number 01 Patient Initial KSK Inte of Farolinest 11 03 1074 Ezrolpunt Number NR1 03 1012 0 Batch Nember 03 Geide Name S.S. W.S. Swetha Third No. FEET STATE XEOVer/skima CONTROLLED COP


FIGURE:-4 Cate Report From Femina No. 18, Dated 61817007 01 SHIPYSH (XXXXYYY) 03 5000 Dich: Mint Rip Mintel Coast Fest Eye, Date of sound signed (DOMNEYYYY) 16 03 200 ("Ne Marsin Dates" M Solvet Intelli K DEMOGRAPHICS (TICK AS APPLICABLE) 164 ᄤ 35 192 06 01 Des of Rich (DAMATTY) how NI VITAL SICHS 22 hoprain Nata Biol News 170 ML 80 ML maps Brain project liquing la Depte Falschill 9-6 Buly Timpenters Polici Nr. NEW SCI.

Volume 6, Issue 4, July. – Aug. 2024 pp 263-272 www.ijdmsrjournal.com ISSN: 2582-6018

FIGURE:-5



FIGURE: -6



Volume 6, Issue 4, July. – Aug. 2024 pp 263-272 www.ijdmsrjournal.com ISSN: 2582-6018

FIGURE:-7



FIGURE:-9




FIGURE:-8

S.m. Gentlemete Brack	Mage,	-	-
	New	-	Tres.
Angel State of the Angel State of the State	-	100	0
An exercising the best reason or will be a like the later.	- 6	m	1
		N/S	12
a little length will take to become from place make top or yet; from it		0	10
The second control of the second seco	-		-
6. Now have property and relies to the party and	_	8	18
the partie of the second to the contract the said the	- 1	1000	150
The particular Property of the Particular Proper	4 2	181	5
T. Didn't that The long too be receiving and receive	10	1	27
What is the discharge over the provide the name of the last	13	3.	3
- Amate		To	13
Total many (Allisting of East Specific	9	10	15.0

bjee	diam't fre	Securit. No.	PERMIT	
				-
for print county	printed of	afaresting of or	of these in a line	tack or floor-o
presentative				
Name of palests	KIK	Pagest Vent	01	
				and the first
X	Commence		V BEE ATTACK	ner hil som
MA	OF OR SET CHE	the Amile of S	maked bull	Sig Serjete
chief Meetin, plan	named sides	door with His D	on and other is	and and a
remitth ("the biferration				
data or presentation or a				
I referred to Silveday				
Carried St.				
3. The beforestive with and every emerge sell	he published with the reads to seen	nat my market bill a necessarie. I co	Example beloft	n sure stude or the constan
Annesty mess be-	presented, h is	position that are	mody anothelic	in-jeties b
marph, southed; w	for for Andreller on	whose distribution in	e, I'll nou inches	and, or a relative
The state of				
The believes in may be madedly as beautiful care.				
* North Add States	es. The below	and the same and	mark to their	and the second of the
, with any third party to			. The informati	n step bestem
To be with the segue the comment to per-	west of any tips Months it will as	the resident	in, the own the	bilionation has
	^	-		-
2/11/20	12		300	
Figure	de-	Desc	Klatu	_
4				A STEEL
			- 6	Parcel
			1	W. E.
			-32	300
-				
His Cologist pieces			Territoria.	N NAMES OF THE PARTY OF

STUDY REPORT

Protocol Title: A non-international data collection study to determine the role of usage of multivitamins capsules in diabetic patient as an add-on therapy.

We have collected 20 patient's data with all required approvals prior to starting the data collection & we have used basic informed consent form of version no 1.0 dated: 01/03/2022 as a proof of acceptance from the patient to collect the

required medical data from them in case report form of version no 1.0 dated: 01/03/2022.

We have divided the 20 patients into two groups & in group A we have collected the data of all 20 patients with diabetic history & group A consuming multivitamins tablets as a add on therapy & group B was non consumers of multivitamin & the total past medical & medication history of both the groups is based on the data collected &post analysis we can observe in the following results. $^{[8]}$


TABLE:-3MULTIVIATMINS CONSUMPTION

SUBJECT ID	GROUP A	SUBJECT ID	GROUP B
1	YES	11	NO
2	YES	12	NO
MVT CONSUMPTIO	N		
3	YES	13	NO
4	YES	14	NO
5	YES	15	NO
6	YES	16	NO
7	YES	17	NO
8	YES	18	NO
9	YES	19	NO
10	YES	20	NO

TABLE:-4 Quality of life based on multivitamins consumption

PATIENTID	MVT	Quality of life	Patient id	MVT	Quality of life
	consumption			consumption	
1	Yes	15	11	No	2
2	Yes	16	12	No	4
3	Yes	13	13	No	2
4	Yes	15	14	No	4
5	Yes	15	15	No	5
6	Yes	17	16	No	2
7	Yes	17	17	No	5
8	Yes	16	18	No	3
9	Yes	12	19	No	4
10	Yes	16	20	No	5
Mean	100%	15.2	Mean	0%	3.6





The bar chart compares the quality of life between two groups, labelled as Group A and Group B. the X-axis represents 10 different categories or intervals, while the Y-axis measures the quality-of-life scores. Group A, represented by the blue bars, consistently shows higher scores across all categories, ranging from approximately 12 to 17 in contrast, Group B depicted by the red

bars, has significantly lower scores in every category, with values ranging from about 1 to 4. This graphical representation indicates a noticeable disparity in the quality of life between the two groups, with Group A having a substantially better quality of life than Group B across all measured categories.

FINAL DATA REPORT

TABLE: -5Comparison of quality of life between group A and group B population

GROUP-A	GROUP-B				
N no of population	10	N no of population	10		
MVT consumption	100%	MVT consumption	0%		
Quality of life	15.2%	Quality of life	3.6%		

The table presents a comparison of the quality of life between two groups, Group A and Group B, both groups have an equal population size of 10 individuals. However, there is a stark contrast in their MVT (likely referring to multivitamins therapy or treatment) consumption: Group A has a 100% MVT consumption rate, while Group B has 0% consumption. This difference in MVT consumption appears to correlate with the

reported quality of life in each group. Group A, with full MVT consumption, has a significantly higher quality of life score of 15.2%, whereas Group B, without any MVT consumption shows a much lower quality of life score of 3.6 %. this suggests a possible link between consumption and an improved quality of life.

II. SUMMARY

In group A, no of population n= 10, we have observed that the mean value of consumption of MVT in diabetic population is 100% and in group B with the mean value of consumption of MVT in diabetic population is 0% and the mean value of quality of life in group A was 15.2% who consuming MVT as an add on therapy and mean value of quality of life in group B was 3.6% who wasnot consumed MVT as an add on therapy.

III. CONCLUSION

The final conclusion of the data collection was that all the diabetic population who are consuming multivitamin as an add on therapy were leading a good quality of life when compared to diabetic population who are not consuming the multivitamin as add on therapy.

REFERENCES

- [1]. https://en.wikipedia.org/wiki/Multivitamin
- [2]. ICH Harmonised Tripartite Guideline—E9(R1). Addendum on Esti ands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials, final version, dated 20th November 2019 (last accessed on 09.03.2022).
- [3]. ICH Harmonised Tripartite Guideline— E9
 Statistical Principles for Clinical Trials
 current step 4 version, dated February
 1998.
- [4]. Gamble C, Krishan A, Stocken D, et al., 2017, Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. JAMA; 318(23):2337-2343, available online, (last accessed 26.02.2019), doi:10.1001/jama.2017.18556.
- [5]. Clinical Development Services Agency SOP for Writing a Statistical Analysis Plan, version 1.0, 2015.
- [6]. Assessment_of_quality_of_life_in_type_II _diabetic_.pdf
- [7]. https://irbrcm.rcm.upr.edu/wp-content/uploads/sites/21/2021/04/UPR-MSC_ICF_English_Template_Rev-13-APR-2021_FINAL.pdf
- [8]. MRCClinical Trials Unit at University College London SOP for Statistical Principles (version 5.0), 2017.